KuartisMED, a biomedical R&D company that develops innovative health technologies for neonatal health and well-being, received an investment of $1.8 million led by APY Ventures and Arya WIP.
KuartisMED, one of the successful startups of the Turkish healthcare industry, announced that it has received an investment of $1.8 million in a seed investment tour led by Arya Women’s Investment Platform and APY Ventures.
Growth Circuit, Techmine, Technology and Innovation Fund, Technology Investment Inc. and Berkay Mollamustafaoglu, which are important players of the Turkish start-up ecosystem, also took part in this investment tour.
KuartisMED, a biomedical research company that designs, develops and manufactures smart, safe and innovative medical products for the well-being of newborns and especially preterm babies; was founded in 2012 by Prof. Dr. Ayse Nur Ecevit, Prof. Dr. Aylin Tarcan, academic physicians with extensive experience and who have worked in the field of Neonatal and Pediatrics for many years, and Dr. Ahmet Saracoglu, who are experts in machine learning, computer vision and signal processing and with the support of the Ministry of Science, Industry and Technology of the Republic of Turkiye, Techno-enterprise.
Newborns, which are of great importance for families and the health system all over the world, and among the 150 million babies born every year, 15 million babies categorized as premature may have very different needs compared to adults. In newborns, especially in preterm infants, feeding ability, also known as nutritional maturation, is important for achieving effective oral feeding, ideal growth and safe discharge from the hospital. NeoSAFE, which was developed for the objective evaluation of nutritional ability, is a medical device that has no equivalent in the world. NeoSAFE, which monitors the breathing and swallowing activities of babies through non-invasive sensors, processes these activities and values with unique machine learning algorithms and produces the report for the analysis of feeding ability, was awarded the most innovative diagnostic technology by the Turkish Neonatology Association in 2021. With NeoSAFE, which was developed for monitoring the nutritional development of all babies in the risk group and for the decision to discharge, KuartisMED supports healthcare professionals in making safe and correct decisions and aims to prevent the effects of nutrition-related health problems of newborns at the beginning of their lives.
With the said investment, KuartisMED will focus on new product development while carrying out the activities of disseminating the product, which has successfully completed CE certification processes, after-sales clinical follow-up, compliance with new markets and regulations, marketing and cooperation development.
Regarding the investment round, KuartisMED co-founder and CEO Dr. Ahmet Saracoglu said; “With the investment tour, we aim to achieve global growth with our international partners in the field of neonatology. In addition, we will continue to develop pioneering practices and products that enable physicians to make accurate and reliable decisions in a field such as neonatology, which is a priority for the health system and receives less attention than it should be in terms of health technologies. We want to be the first choice for health professionals, newborns and their families with our product family in the digital health vertical that we will present to the market in the coming period.”
Ahu Serter, Founder of Arya Women’s Investment Platform, said the following about KuartisMED’s investment: “Arya Women’s Investment Platform; In addition to determining gender-balanced entrepreneurship criteria since the day it was founded, it has been playing an important role in the development of start-ups in this field by dealing with technology-oriented initiatives for the last two years. At Arya, we started to invest in startups that develop deep technologies, and KuartisMED is one of them. The KuartisMED investment is an important investment for us both to support life sciences and to pioneer the emergence of high-tech startups. The participation of Prof. Dr. Ayse Nur Ecevit and Prof. Dr. Aylin Tarcan, two valuable medical doctors, in this initiative and their work on a technology that will prevent neonatal deaths is one of the important outputs that will support our mission at Arya.”
Emin Ozer, General Manager of Albaraka Portfolio; “As APY Ventures, we are happy to co-lead the investment tour of KuartisMED, which operates in the field of health technologies. With the NeoSafe product they have developed for the well-being of newborns, they will provide a serious decrease in complication and death rates with the support they will provide to doctors in the decision to discharge premature babies. We will continue to support the ecosystem with our Informatics Valley Fund, which focuses on initiatives that develop hardware in the field of health.”
Source: Egirisim / Translated by Irem Yildiz